KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $468.0 million.

  • Biogen's Free Cash Flow fell 3514.41% to $468.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.1 billion, marking a year-over-year decrease of 2465.28%. This contributed to the annual value of $2.1 billion for FY2025, which is 2465.28% down from last year.
  • Latest data reveals that Biogen reported Free Cash Flow of $468.0 million as of Q4 2025, which was down 3514.41% from $1.2 billion recorded in Q3 2025.
  • Biogen's Free Cash Flow's 5-year high stood at $1.2 billion during Q3 2025, with a 5-year trough of -$261.4 million in Q4 2022.
  • For the 5-year period, Biogen's Free Cash Flow averaged around $528.4 million, with its median value being $555.2 million (2023).
  • In the last 5 years, Biogen's Free Cash Flow crashed by 13322.74% in 2022 and then surged by 146926.0% in 2024.
  • Quarter analysis of 5 years shows Biogen's Free Cash Flow stood at $786.7 million in 2021, then tumbled by 133.23% to -$261.4 million in 2022, then surged by 79.84% to -$52.7 million in 2023, then skyrocketed by 1469.26% to $721.6 million in 2024, then crashed by 35.14% to $468.0 million in 2025.
  • Its last three reported values are $468.0 million in Q4 2025, $1.2 billion for Q3 2025, and $134.3 million during Q2 2025.